The next step in the clinical evaluation of LRRK2 inhibition for #Parkinsons begins: Denalitx and Biogen have initiated dosing in the Phase 2b LUMA study to evaluate the efficacy & safety of BIIB122 (DNL151 vs placebo) in 640 participants with early-stage PD
Denalitx and Biogen have initiated dosing... - Cure Parkinson's
Denalitx and Biogen have initiated dosing in the Phase 2b LUMA study to evaluate efficacy & safety of BIIB122 (DNL151 vs placebo)
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
New clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
New clinical trial registered:
NeuromedIRCCS researchers have registered a small (N=20) open...
AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
AnnovisBio has initiated a 6-month, placebo-controlled, double-blind Phase 2 study to evaluate...
More effective access to the brain . . . probably what Biogen sees in partnering with Denali Therapeutics
Denali Therapeutics certainly seems to be in the “fast lane” in using their proprietary ETV...
Update on Affiris Vaccine - Phase 1 results
Inosine, Israpidine, NAC, Glutathione clinical trials - Love to hear from those who have experience with these.
Gene therapy is underway!
Ultra-powerful brain scanners offer hope for treating cognitive symptoms in Parkinson’s disease
